Matthew Edwards

Advised BioNTech SE  on its acquisition of InstaDeep Ltd, a leading global technology company in the field of artificial intelligence and machine learning, for to total consideration of up to £562 million.

Advised Icon Group, Australia's leading oncology provider, on its acquisition of Cancer Centre London.

Advised BioNTech SE, on its investment in Crescendo Biologics in connection with a wider multi-target discovery collaboration to develop novel immunotherapies for the treatment of patients with cancer and other diseases.

Advised Constructive.Bio, the pioneering synthetic genomics company, on its $58 million Series A Financing round.

Advised shareholders of Foodsteps, the UK-based environmental impact assessment platform, on its acquisition by Registrar Corp, a Paine Schwartz Partners' company.

Advised Basecamp Research Ltd ("Basecamp"), a company that designs protein products based on the largest knowledge graph of natural biodiversity in existence, on a $20 million Series A funding round led by climate investor, Systemiq Ventures.

Advised WG Partners LLP, Panmure Gordon (UK) Limited and Stifel Nicolaus Europe Limited on the conditional £34.3 million placing for AIM-quoted Redx Pharma plc, the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease. 

Advised global healthcare leader Grifols on the agreement with the Hong Kong’s Tiancheng International Investment Ltd. to acquire 100% of the shares of Tiancheng Pharmaceutical Holdings AG, which holds approximately a stake of 89.88% of Biotest ordinary shares and 1.08% of Biotest preferred shares for approximately EUR1.1bn.  

Advised Endeavour Vision on its investment in Lumeon, a leader in care pathway orchestration. The investment is part of Lumeon's $30M Series D investment round.

Advised AIM-quoted hVIVO plc, an industry leading services provider in viral challenge studies and laboratory services, in relation to its recommended proposed £12.96 million all-share merger with Open Orphan plc.  

Advised RHYTHM AI, a UK company focused on the treatment of Atrial Fibrillation (AF), on the closure of its seed financing, and various follow-on financing rounds. 

Advised Turbine, a company simulating cellular decision making to unlock novel oncology therapies, on raising EUR 5.7 million (USD 6.85m) as part of the successful closing of its pre-Series A round, and various follow-on financing rounds. 

Advised SCVC, a leading UK VC investing in early-stage deep tech spin-outs, on its portfolio investments including Imophoron, Forefront RF, Carbometrics, Portal Biotech and Scarlet Therapeutics. 

Advised Uniphar plc on the acquisitions of UK-based brand commercialisation and pharmaceutical marketing agency, Events4Healthcare, and UK-based pharmaceutical distributor Devonshire Healthcare Services.

Advised the shareholders of The Research Partnership Limited (Research Partnership) on its acquisition by Ashfield Huntsworth for an undisclosed amount .

Advised Mogrify, a biopharmaceutical company transforming the lives of patients through a novel class of in vivo reprogramming therapies, on its $46 million Series A financing round.